Literature DB >> 26179427

Bee venom enhances the differentiation of human regulatory T cells.

I Caramalho1, A Melo1, E Pedro2, M M P Barbosa2, R M M Victorino1,2, M C Pereira Santos1, A E Sousa1.   

Abstract

Venom-specific immunotherapy (VIT) is well recognized by its efficacy, and compelling evidence implicates regulatory T cells (Tregs) in the underlying tolerogenic mechanisms. Additionally, hymenoptera venom has for a long time been claimed to modulate immunity. Here, we investigated the putative role of bee venom (Bv) in human FOXP3-expressing Treg homeostasis and differentiation, irrespective of the donors' allergic status. We found that Bv significantly enhanced the differentiation of FOXP3-expressing cells both from conventional naïve CD4 T cells and mature CD4 thymocytes, a property that may contribute to the VIT's capacity to expand circulating Tregs in allergic individuals. We expect that our data enlightening the Treg-mediated immunomodulatory properties of Bv regardless of TCR specificity, to have application in other allergies, as well as in other clinical settings, such as autoimmunity and transplantation.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bee venom; regulatory T cells; venom-specific immunotherapy

Mesh:

Substances:

Year:  2015        PMID: 26179427     DOI: 10.1111/all.12691

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  9 in total

Review 1.  Biological Effects of Animal Venoms on the Human Immune System.

Authors:  Zharick Avalo; María Claudia Barrera; Manuela Agudelo-Delgado; Gabriel J Tobón; Carlos A Cañas
Journal:  Toxins (Basel)       Date:  2022-05-16       Impact factor: 5.075

2.  Expression of eosinophils, RANTES and IL-25 in the first phase of Hymenoptera venom immunotherapy.

Authors:  Krzysztof Pałgan; Magdalena Żbikowska-Götz; Zbigniew Bartuzi
Journal:  Postepy Dermatol Alergol       Date:  2019-04-01       Impact factor: 1.837

3.  Time-dependent effect of desensitization with wasp venom on selected parameters of the immune system.

Authors:  Łukasz Szymański; Weronika Urbańska; Martyna Ciepielak; Aleksandra Cios; Wanda Stankiewicz; Marta Stelmasiak; Agnieszka Rzeszotarska; Jolanta Korsak; Sławomir Lewicki; Andrzej Chciałowski
Journal:  Sci Rep       Date:  2022-05-03       Impact factor: 4.379

Review 4.  Bee Venom Phospholipase A2: Yesterday's Enemy Becomes Today's Friend.

Authors:  Gihyun Lee; Hyunsu Bae
Journal:  Toxins (Basel)       Date:  2016-02-22       Impact factor: 4.546

5.  Bee venom and SARS-CoV-2.

Authors:  Wei Yang; Fu-Liang Hu; Xiao-Feng Xu
Journal:  Toxicon       Date:  2020-04-30       Impact factor: 3.033

Review 6.  Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections.

Authors:  Keneth Iceland Kasozi; Gniewko Niedbała; Mohammed Alqarni; Gerald Zirintunda; Fred Ssempijja; Simon Peter Musinguzi; Ibe Michael Usman; Kevin Matama; Helal F Hetta; Ngala Elvis Mbiydzenyuy; Gaber El-Saber Batiha; Amany Magdy Beshbishy; Susan Christina Welburn
Journal:  Front Public Health       Date:  2020-12-10

7.  Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2: Antiviral Screening and Molecular Docking Studies.

Authors:  Mohammed W Al-Rabia; Nabil A Alhakamy; Osama A A Ahmed; Khalid Eljaaly; Ahmed L Aloafi; Ahmed Mostafa; Hani Z Asfour; Ahmed A Aldarmahi; Khaled M Darwish; Tarek S Ibrahim; Usama A Fahmy
Journal:  Pharmaceutics       Date:  2021-02-26       Impact factor: 6.321

Review 8.  Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2).

Authors:  William G Lima; Júlio C M Brito; Waleska S da Cruz Nizer
Journal:  Phytother Res       Date:  2020-09-18       Impact factor: 6.388

Review 9.  Harnessing the Natural Toxic Metabolites in COVID-19.

Authors:  Ali Bahrami; Mohammad Taheri; Mohammad Reza Arabestani; Meysam Soleimani; Mojdeh Mohammadi; Fatemeh Golabchi; Maryam Banitorfi; Seyed Mostafa Hosseini; Sodabe Khodabandehlou; Fatemeh Nouri
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-07       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.